|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday after the medical-device maker reported second-quarter earnings that topped Wall Street expectations and raised full-year guidance, though the company missed expectations for revenue. Profit for the latest quarter rose to $1.465 billion, or 56 cents a share, from $733 million, or 41 cents a share, from the year-earlier quarter. Adjusted EPS was 82 cents, topping the FactSet consensus of 80 cents. Revenue rose 2.7% to $7.979 billion from $7.767 billion a year ago. Analysts polled by FactSet had expected $7.997 billion in sales. Sales of the company's nutrition unit rose 0.9% to $1.875 billion, while the diagnostics sales rose 1.7% to $1.905 billion. Sales of the established pharmaceuticals business fell 1.8% to $1.108 billion, while sales of the medical devices unit rose 6.4% to $3.075 billion, boosted by strong sales of the company's FreeStyle Libre glucose monitoring system and MitraClip. Abbott raised its full-year EPS to between $3.21 and $3.27 from between $3.15 and $3.25. "Our sales growth accelerated and is sustainable," Abbott's Chief Executive Miles D. White said in a statement. "We have great momentum and are raising our guidance above the strong outlook we previously set for the year." Shares of Abbott have gained 15% so far this year through Tuesday, while the S&P 500 has gained 19.8%.
NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern ...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Abbott Laboratories. Global Credit Research- 26 Jun 2019. New York, June 26, 2019-- Moody's Investors Service ...
Prepare for more churn around these levels, said Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.
Moody's Investors Service ("Moody's") upgraded the senior unsecured ratings of Abbott Laboratories' ("Abbott") and its guaranteed subsidiary Abbott Ireland Financing DAC's to A3 from Baa1. Moody's also affirmed Abbott's commercial paper rating at Prime-2. The upgrade reflects Moody's expectations that Abbott will continue to operate with moderate financial leverage with debt/EBITDA sustained below 3.0 times.
The largest Insider Buys this week were for Abbott Laboratories, Morgan Stanley, Crown Castle International Corp and Pinterest Inc.
ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Diabetes Care revenues In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a
ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Abbott Laboratories’ Segmental performanceIn its first-quarter earnings conference call, Abbott Laboratories (ABT) guided for mid-single-digit growth for its
ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Margin guidance In its first quarter earnings conference call, Abbott Laboratories (ABT) guided for a fiscal 2019 adjusted gross margin ratio of 59.5% driven by
ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Revenue guidance In its first-quarter earnings conference call, Abbott Laboratories (ABT) reiterated its YoY organic sales growth rate of 6.5%–7.5% for fiscal 2019.
ABT or BSX: Which Is a More Attractive Pick in April?(Continued from Prior Part)Abbott’s performance in the first quarter Abbott Laboratories (ABT) released its first-quarter earnings on April 17. The company reported revenues of $7.54 billion, a
ABT or BSX: Which Is a More Attractive Pick in April?Stock price movements On April 18, Abbott Laboratories (ABT) closed at $73.92, 1.43% higher than its previous closing price, 30.12% higher than its 52-week low of $56.81, and 8.45% below its
Jeff Jonas of Gabelli talks about a closed-end fund that invests in the health-care and consumer staples sectors.
Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.
Abbott Laboratories' earnings and sales topped first-quarter estimates, but the medical products giant retained its prior full-year outlook and Abbott stock slipped at the close Wednesday.